Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance

Author:

Jaksa Ashley1ORCID,Wu James2ORCID,Jónsson Páll3ORCID,Eichler Hans-Georg4ORCID,Vititoe Sarah1ORCID,Gatto Nicolle M1ORCID

Affiliation:

1. Scientific Research, Aetion Inc., 5 Penn Plaza, 7th Fl., New York, NY 10001, USA

2. Amgen Inc, 1 Amgen Center Drive, Thousand Oaks, CA 91320-1779, USA

3. National Institute for Health & Care Excellence, Level 1A, City Tower, Piccadilly Plaza Manchester, M1 4BT, UK

4. European Medicines Agency, Domenico Scarlattilaan 6, Amsterdam 1083 HS, Netherlands

Abstract

Decision-makers have become increasingly interested in incorporating real-world evidence (RWE) into their decision-making process. Due to concerns regarding the reliability and quality of RWE, stakeholders have issued numerous recommendation documents to assist in setting RWE standards. The fragmented nature of these documents poses a challenge to researchers and decision-makers looking for guidance on what is ‘high-quality’ RWE and how it can be used in decision-making. We offer researchers and decision-makers a structure to organize the landscape of RWE recommendations and identify consensus and gaps in the current recommendations. To provide researchers with a much needed pathway for generating RWE, we discuss how decision-makers can move from fragmented recommendations to comprehensive guidance.

Publisher

Future Medicine Ltd

Subject

Health Policy

Reference77 articles.

1. National Institute for Health and Care Excellence. Increasing use of health and social care data in guidance development (2020). www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/how-we-develop-nice-guidelines/data-and-analytics-statement-of-intent

2. US Food and Drug Administration. Framework for FDA's Real-World Evidence Program (2018). www.fda.gov/media/120060/download

3. European Medicines Agency. EMA Regulatory Science to 2025 (2020). www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf

4. Office of the Commissioner. Coronavirus (COVID-19) Update: FDA Collaborations Promote Rigorous Analyses of Real-World Data to Inform Pandemic Response. FDA (2020). www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-collaborations-promote-rigorous-analyses-real-world-data-inform

5. The Magic of Randomization versus the Myth of Real-World Evidence

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3